Gerhard Nehmiz

Biberach An Der Riss, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Safety, tolerability, and pharmacokinetics of faldaprevir after single increasing doses in healthy subjects.

Safety, tolerability, and pharmacokinetics of faldaprevir after single increasing doses in healthy subjects.

Journal: Frontiers in pharmacology

Published: July 15, 2025

Bayesian Phase II optimization for time-to-event data based on historical information.

Bayesian Phase II optimization for time-to-event data based on historical information.

Journal: Statistical methods in medical research

Published: December 30, 2017

The predictive distribution of the residual variability in the linear-fixed effects model for clinical cross-over trials.

The predictive distribution of the residual variability in the linear-fixed effects model for clinical cross-over trials.

Journal: Biometrical journal. Biometrische Zeitschrift

Published: November 18, 2015

An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery.

An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery.

Journal: Thrombosis research

Published: November 17, 2015

Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients.

Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients.

Journal: The Journal of pharmacology and experimental therapeutics

Published: September 11, 2014

Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C.

Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C.

Journal: Antimicrobial agents and chemotherapy

Published: July 17, 2013

Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results.

Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results.

Journal: Antiviral therapy

Published: March 17, 2013

The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

Journal: Journal of the American College of Cardiology

Published: March 11, 2013

Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.

Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.

Journal: Hepatology (Baltimore, Md.)

Published: January 25, 2013

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.

Journal: Hepatology (Baltimore, Md.)

Published: September 17, 2012

Response to the letter by Dr Chin and co-workers.

Response to the letter by Dr Chin and co-workers.

Journal: British journal of clinical pharmacology

Published: July 06, 2012

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects.

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects.

Journal: Clinical pharmacology in drug development

Published: May 08, 2012

Showing 1-12 of 14

Last Updated: 09/26/2026